Exclusive: Forbion-backed cardio biotech rebrands to RyCarma with Phase 2 plans

Kyle LaHucik

Senior Reporter

A 20-year-old biotech working on small molecule treatments for cardiovascular and skeletal muscle diseases has rebranded and plans to enter Phase 2 in heart failure …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Forbion-backed cardio biotech rebrands to RyCarma with Phase 2 plans

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Judge halts some NIH cuts after 22 states sue

States sue Trump administration over billions in NIH indirect cost cuts

Hims’ Super Bowl ad has drawn criticism from lawmakers — and now Novo Nordisk

Eli Lilly inks $630M deal for Phase 1 MASH candidate

Merck KGaA confirms interest in acquiring cancer biotech SpringWorks

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Ex­clu­sive: For­bion-backed car­dio biotech re­brands to RyCar­ma with Phase 2 plans

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Exclusive: Forbion-backed cardio biotech rebrands to RyCarma with Phase 2 plans